Abstract
Background Research on the effectiveness of pharmacotherapies for schizophrenia-substance use disorder comorbidity (Sch-SUD) is very sparse and non-existent on the prevention of the development of substance use disorders (SUD) in patients with schizophrenia.
Aims To compare the real-world effectiveness of antipsychotics in schizophrenia in decreasing risks of: 1) development of an initial SUD; and 2) psychiatric hospitalization and hospitalization due to SUD among patients with SUD.
Methods Two independent national cohorts including all persons diagnosed with schizophrenia (N=45,476) were followed up for 22 (Finland: 1996–2017) and 11 years (Sweden: 2006–2016). Risks of developing SUD were calculated with between-individual models, and risks of psychiatric and SUD hospitalization with within-individual models using Cox regression and adjusted Hazard Ratios (aHRs) when using vs. not using certain antipsychotics.
Results For schizophrenia patients without SUDs, clozapine use (aHR 0.20, 95%CI 0.16–0.24, p<0.001, in Finland; 0.35, 0.24–0.50, p<0.001, in Sweden) was associated with lowest risks of developing an initial SUD in both countries. Antipsychotic polytherapy was associated with second lowest risk (0.54, 0.44-0.66) in Sweden, and third lowest risk (0.47, 0.42-0.53) in Finland. Risks of psychiatric hospitalization and hospitalization due to SUD were lowest during use of clozapine, antipsychotic polytherapy, and long-acting injectables in both countries. Results were consistent across both countries.
Conclusion Clozapine and antipsychotic polytherapy are most strongly associated with reduced chances of developing SUDs among patients with schizophrenia and with lower relapse rates among patients with both diagnoses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Finnish Ministry of Social Affairs and Health through the developmental fund for Niuvanniemi Hospital. HT was funded by Academy of Finland (grants 315969, 320107). ML was partly funded by personal grants from the Finnish Medical Foundation and Emil Aaltonen foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Regional Ethics Board of Stockholm approved this research project (decision 2007/762 31). Permissions were also granted by pertinent institutional authorities at the Finnish National Institute for Health and Welfare (permission THL/847/5.05.00/2015), the Social Insurance Institution of Finland (65/522/2015), and Statistics Finland (TK53-1042 15). The study was registry-based and no contact was made with the participants of the study; therefore, according to legislation in both countries and as per our previous publications, obtaining informed consent from participants was not required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets analysed in this study are not publicly available due to participant privacy and security concerns. Researchers can apply for access to these data from the register holders: for Finnish data with the Social Insurance Institution of Finland (Prescription Register), the Finnish National Institute for Health and Welfare (Hospital Discharge Register), and Statistics Finland (Causes of Death Register); for Swedish data with National Board of Health and Welfare (National Patient Register, Prescribed Drug Register), Statistics Sweden Death and sociodemographic data in LiSA register), and the Swedish Social Insurance Agency (MiDAS register).
